| Name | Title | Contact Details |
|---|
Sonrava Health is the parent organization of a national family of health and wellness companies, united by a singular dedication to delivering high-quality, convenient and affordable care through innovative provider models, health coverage and product offerings. Building on a proven platform of success, the brand will continue to expand access to dental and vision care with a mission of advancing whole-person health for patients from all backgrounds. A geographically diverse, multi-specialty organization with a unique mix of providers and payors, Sonrava Health is comprised of several companies – including Western Dental & Orthodontics, Western Dental Kids, Brident Dental & Orthodontics, Brident Dental Kids, LooksBrite Eye Centers, EyeMax Vision Plan, MIB Insurance Plans, Vital Smiles, MID-Atlantic Dental Partners, DentalWorks, and Perfect Teeth – all united in our commitment to quality, value and innovation in care.
Putnam County Operation Life is a Greencastle, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical Innovations develops, manufactures and markets state-of-the-art medical devices that improve healthcare outcomes for clinicians and their patients worldwide. With particular emphasis on healthcare solutions for women and their infants, Clinical Innovations employs high quality standards in every aspect of business to make advancements in technology and bring innovative ideas to life.
For 20 years, ReMed has provided exceptional neurologic rehabilitation services to enhance community integration, economic independence and the development of a productive and fulfilling lifestyle. Comprehensive reality-based treatment plans are
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.